PBL InterferonSource, Neutekbio Plan to Co-Develop ‘Ready-to-Go’ Cytokine Assays | GenomeWeb
PHILADELPHIA — PBL InterferonSource and Neutekbio plan to jointly develop and market what they have dubbed “ready-to-go” cell-based assay kits based on Neutekbio’s proprietary iLite technology, which is designed to detect and quantify cytokine activity.
Terms of the deal, signed in April, call for PBL to provide interferons and other cytokines to Neutekbio, which will develop an assay that can detect and measure the activity in the cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.